Nuijten M J
Lewin Group, Hoofddorp, The Netherlands.
Pharmacoeconomics. 1998 Mar;13(3):305-16. doi: 10.2165/00019053-199813030-00005.
Economic analysis has become increasingly important in healthcare in general, and particularly with respect to pharmaceuticals. Therefore, it is vital that the methods used in such evaluations are carefully scrutinised and refined. However, guidelines contain only a limited number of recommendations for the use of secondary data in modelling studies. In this manuscript, the selection of data sources in modelling studies will be addressed. The objectives of this manuscript are as follows: (i) to present a general strategy on how to determine the appropriateness of a data source for a model; and (ii) to present recommendations on a transparent reporting format for the selection of data sources.
一般而言，经济分析在医疗保健领域，尤其是在制药方面，已变得越来越重要。因此，对这类评估中所使用的方法进行仔细审查和完善至关重要。然而，指南中关于在建模研究中使用二手数据的建议数量有限。在本手稿中，将探讨建模研究中数据来源的选择。本手稿的目标如下：(i) 提出一个关于如何确定模型数据源适用性的总体策略；(ii) 就数据源选择的透明报告格式提出建议。
